Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • RFK Jr.
  • Hantavirus Outbreak
  • AI in Healthcare
  • Makary Resigns
  • Pancreatic Cancer Drug

WHAT'S NEW

  • RFK Jr.
  • Hantavirus Outbreak
  • AI in Healthcare
  • Makary Resigns
  • Pancreatic Cancer Drug

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Sep 1 2020

Full Issue

FDA Head Promises Honest Science On Vaccine Approval

Stephen Hahn, the FDA commissioner, vows to resist pressure to release a COVID vaccine before it's ready. He suggests he would resign if he can't resist it.

CNN: FDA Commissioner Says He Would Consider Resignation If Asked To Release A Coronavirus Vaccine Too Early 

The commissioner of the US Food and Drug Administration said "all options are on the table" when asked if he would resign if pressured to release a coronavirus vaccine before he feels it's ready. "I can tell you, our decision at FDA will not be made on any other criteria than the science and data associated with these clinical trials," Dr. Stephen Hahn told CBS. (Holcombe, 9/1)

CBS News: COVID-19 Vaccine Will Be Made Available "On The Basis Of Science And Data," FDA Commissioner Says 

The commissioner said, depending on that data, it's possible a vaccine could be available by Election Day under the Emergency Use Authorization program - before a Phase III trial is completely finished. Hahn acknowledged the pressure his agency faces to approve a vaccination. "There's been pressure throughout this pandemic and I think anybody who doesn't acknowledge that would be kidding themselves. There's been pressure to make sure that we get medical products as quickly as possible to the American people," Hahn said.(Lapook, 8/31)

In related developments —

The Wall Street Journal: Covid-19 Vaccines: What’s Coming And When? 

Some 170 Covid-19 vaccines are in development around the world, according to the World Health Organization, each one promising to protect people from the deadly coronavirus and allow them to go back to work and school. Now, a handful are starting or nearing the final stage of testing. Depending on the results, some companies say their vaccines could be greenlighted for use as soon as this year. (Rivas, Loftus and Cervantes, 8/31)

Politico: What Happens If China Gets The Covid-19 Vaccine First? 

David Fidler has a nightmare scenario: In three months, China announces one of its Covid-19 vaccines has successfully completed Phase III trials. The World Health Organization is enthusiastic. Beijing doles out doses to countries in Latin America and Africa and those with claims to the South China Sea. The United States is nowhere to be found. “If China wins the race, exploits that advantage and we don’t have anything equivalent yet, what do we do?” he asks. “That to me is what concerns me the most.”

CNN: Past Vaccine Disasters Show Why Rushing A Coronavirus Vaccine Now Would Be 'Colossally Stupid' 

Vaccine experts are warning the federal government against rushing out a coronavirus vaccine before testing has shown it's both safe and effective. Decades of history show why they're right. (Christensen, 9/1)

NBC News: Large Trials For The Oxford COVID-19 Vaccine Begin In The U.S.

Phase 3 clinical trials for the much-anticipated Oxford COVID-19 vaccine are set to begin in the United States Tuesday, with participants in Madison, Wisconsin rolling up their sleeves for the injection. The University of Wisconsin is one of dozens of test sites in the U.S. for the vaccine candidate, made by AstraZeneca in partnership with the U.K.'s University of Oxford. Tuesday's trial will mark the start of the third phase 3 trial in the U.S. for a COVID-19 vaccine, following Moderna and Pfizer. (Edwards, 8/31)

Reuters: AstraZeneca, Oxford Biomedica Expand COVID-19 Vaccine Supply Tie-Up 

AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker’s COVID-19 vaccine candidate, as it looks to scale-up supply ahead of a possible fast-track approval from the United States. Gene and cell therapy firm Oxford Biomedica said on Tuesday AstraZeneca would give it 15 million pounds ($20 million) upfront to reserve manufacturing capacity at its plant and that it could get an additional 35 million pounds plus other costs until the end of 2021 under the new 18-month deal. (9/1)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 13
  • Tuesday, May 12
  • Monday, May 11
  • Friday, May 8
  • Thursday, May 7
  • Wednesday, May 6
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF